-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 MBJL1g9kPvyqKYiX3ZIr2nrGNIjqvd1wtFpLyWaZx55Ltl32fSHLGCKaT5mmh6X5
 qy1exVuzHmpgKmIsaN1asQ==

<SEC-DOCUMENT>0001144204-08-016674.txt : 20080321
<SEC-HEADER>0001144204-08-016674.hdr.sgml : 20080321
<ACCEPTANCE-DATETIME>20080320190436
ACCESSION NUMBER:		0001144204-08-016674
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080320
FILED AS OF DATE:		20080321
DATE AS OF CHANGE:		20080320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		08703757

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v107607_6k.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vintage-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
      <div>
        <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
        <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
      </div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
        STATES</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
        AND EXCHANGE COMMISSION</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
        D.C. 20549</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
        6-K</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
        of Foreign Private Issuer</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
        to Rule 13a-16 or 15d-16 </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
        the Securities Exchange Act of 1934</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        March
        20, 2008</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
        File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>XTL
        Biopharmaceuticals Ltd.</u></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
        of registrant's name into English)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>711
        Executive Blvd., Suite Q</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Valley
        Cottage, New York 10989</u></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
        of principal executive offices)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark whether the registrant files or will file annual reports under
        cover Form 20-F or Form 40-F.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div align="center">
        <table bgcolor="white" cellpadding="0" cellspacing="0" width="50%">

            <tr bgcolor="white">
              <td width="25%">&#160;</td>
              <td width="25%"><font size="2">Form 20-F <font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font></td>
              <td width="25%"><font size="2">Form 40-F <font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></td>
              <td width="25%">&#160;</td>
            </tr>

        </table><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(1): ____</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(7): ____</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark whether by furnishing the information contained in this Form,
        the
        registrant is also thereby furnishing the information to the Commission pursuant
        to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div align="center">
        <table bgcolor="white" cellpadding="0" cellspacing="0" width="50%">

            <tr bgcolor="white">
              <td width="20%">&#160;</td>
              <td width="20%"><font size="2">Yes <font style="FONT-FAMILY: Wingdings">o</font></font></td>
              <td width="20%"><font size="2">No <font style="FONT-FAMILY: Wingdings">x</font></font></td>
              <td width="20%">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
        is marked, indicate below the file number assigned to the registrant in
        connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
        N/A
</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br>&#160;</div>
      <div>
        <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
        <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
      </div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div><img src="v107607_logo.jpg" alt=""><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Incorporation
          by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated March
          20, 2008
          is hereby incorporated by reference into the registration statements on
          Form F-3
          (File No. 333-141529 and File No. 333-147024) filed by XTL Biopharmaceuticals
          Ltd. with the Securities and Exchange Commission on March 23, 2007 and
          October
          30, 2007, respectively </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>and
          the registration statements on Form S-8 (File No. 333-148058 and File No.
          333-148574) filed by XTL Biopharmaceuticals Ltd. with the Securities and
          Exchange Commission on December 14, 2007 and January 18, 2008,
          respectively.</strong></font></div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
          Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre-Clinical
          Program in Hepatitis C to Presidio Pharmaceuticals</strong></font></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Valley
        Cottage, NY, March 20, 2008 - XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB,
        TASE:
        XTL) announced the licensing of its pre-clinical program in Hepatitis C focused
        on the NS5A target (the &#8220;Program&#8221;) to San-Francisco based Presidio
        Pharmaceuticals, Inc. Presidio is a private biotechnology company focused
        on the
        development and commercialization of anti-viral therapeutics and is backed
        by
        some of the most prominent investors in the biotechnology sector, including
        Panorama Capital, Bay City Capital, Baker Brothers Investments, and Ventures
        West. Presidio&#8217;s scientific team is headed by Dr. Richard Colonno, who until
        recently was Vice President of Infectious Disease Drug Discovery at
        Bristol-Myers Squibb, where he was responsible for Bristol-Myers Squibb&#8217;s
        antiviral drug discovery efforts, including their Hepatitis C and B and HIV
        programs.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
        the
        license agreement, Presidio becomes responsible for all further development
        and
        commercialization activities and costs relating to the Program. XTL will
        receive
        an upfront payment of $4 million, and up to an additional $104 million upon
        reaching certain development and commercialization milestones. In addition,
        XTL
        will receive a royalty on direct product sales by Presidio, and a percentage
        of
        Presidio&#8217;s income if the Program is sublicensed by Presidio to a third party.
</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ram
        Waisbourd, Vice President of Business Development of XTL, commented: &#8220;We have
        great confidence in Presidio&#8217;s ability to move the Program forward rapidly. We
        believe that Presidio has a dynamic and experienced management team, and
        a solid
        scientific team headed by Dr. Richard Colonno - who was a major contributor
        to
        the discovery and advancement of several antiviral drug candidates into clinical
        trials, two of which, atazanavir for HIV, and entecavir for Hepatitis B,
        are
        currently approved drugs.&#8221;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
        Bentsur, XTL&#8217;s CEO commented: &#8220;We are excited about this licensing transaction
        with a motivated and capable partner such as Presidio. This transaction allows
        us to solidify our financial position by bringing in $4 million dollars in
        cash
        and eliminating the ongoing development expense of the Program, while preserving
        a significant share in the Program&#8217;s future success. We believe that this
        transaction extends our financial resources well into Q1 2009, and provides
        us
        with a financial cushion as we head towards the completion and announcement
        of
        results from the Bicifadine Phase 2b study, expected in Q4 2008.&#8221; </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Program focuses on the development of novel small molecule inhibitors against
        the Hepatitis C virus, and is presently in advanced stages of lead optimization.
        The current lead compounds target NS5A - a viral protein that is essential
        for
        viral production. NS5A is distinct from the protease and polymerase. The
        Program&#8217;s lead compounds are highly potent inhibitors of viral replication in
        the replicon assay, which is known to have good correlation with clinical
        efficacy and is currently the leading method for preclinical testing of
        inhibitors of the Hepatitis C Virus. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
        XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
        Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the development of therapeutics
        for the treatment of diabetic neuropathic pain and HCV. XTL is developing
        Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment
        of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL
        has
        out-licensed its novel pre-clinical HCV small molecule inhibitor program.
        XTL
        also has an active in-licensing and acquisition program designed to identify
        and
        acquire additional drug candidates. XTL is publicly traded on the NASDAQ
        and
        Tel-Aviv Stock Exchanges (NASDAQ: XTLB; TASE: XTL).</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Contact:</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
        Bentsur, Chief Executive Officer</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
        +1-(845)-267-0707 ext. 225</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
        PRESIDIO</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Presidio
        Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the
        discovery, in-licensing, development and commercialization of novel therapeutics
        for viral infections, including HIV and HCV. Presidio has raised over $27
        million in financing from Panorama Capital, Baker Brothers Investments, Bay
        City
        Capital, Ventures West, Nexus Medical Partners, and Sagamore Bioventures.
        For
        more information, please visit our website at </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.presidiopharma.com</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Contact:</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Omar
        K.
        Haffar, Ph.D.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President
        and Chief Executive Officer</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>omar@presidiopharma.com</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">415-655-7561</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Cautionary
        Statement</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Some
        of the statements included in this press release, particularly those
        anticipating future financial performance, clinical and business prospects
        for
        our clinical compound for neuropathic pain, Bicifadine, and for our pre-clinical
        compounds for hepatitis C from our XTL-DOS program, growth and operating
        strategies and similar matters, may be forward-looking statements that involve
        a
        number of risks and uncertainties. For those statements, we claim the protection
        of the safe harbor for forward-looking statements contained in the Private
        Securities Litigation Reform Act of 1995. Among the factors that could cause
        our
        actual results to differ materially is our ability to complete in a timely
        and
        cost effective manner clinical trials on Bicifadine, which could directly
        impact
        our ability to continue to fund our operations; our ability to meet anticipated
        development timelines for all of our drug candidates due to recruitment,
        clinical trial results, manufacturing capabilities or other factors; the
        success
        of our drug development and marketing arrangements with third
        parties;</em></font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>and
        other risk factors identified from time to time in our reports filed with
        the
        Securities and Exchange Commission, including our annual report on Form 20-F
        filed with the Securities and Exchange Commission on March 23, 2007. Any
        forward-looking statements set forth in this press release speak only as
        of the
        date of this press release. We do not intend to update any of these
        forward-looking statements to reflect events or circumstances that occur
        after
        the date hereof. This press release and prior releases are available at
        http://www.xtlbio.com. The information in our website is not incorporated
        by
        reference into this press release and is included as an inactive textual
        reference only.</em></font></div><br>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the requirements of the Securities Exchange Act of 1934, as amended, the
        registrant has duly caused this report to be signed on its behalf by the
        undersigned, thereunto duly authorized.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
        <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr valign="top" bgcolor="#ffffff">
              <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
              <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
              <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>XTL
                BIOPHARMACEUTICALS LTD.</strong></font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:&#160;March
                20, 2008</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;Ron
                Bentsur </font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
              <td align="left">
                <hr style="COLOR: black" align="left" noshade size="2" width="50%"><font size="2">Ron
                Bentsur </font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
              <td>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
                  Executive Officer
</font></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>v107607_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v107607_logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``]`(P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^N5^(7BV
M3P;X8.H00)-=2S+!`LF=@<@G+8P<`*>._%8_Q:\)S:[X>_M+3]XU#3E9]L9(
M,L75EXZD8W#Z$#[U>.^![^SO-0?P]KLDCZ5JQ2,OO^:"<']W(I.<')*GL0W.
M0,5UT*"E'VE[VW1SU:KC+D[]3T3X;?%+5=?\1KHNLI!(;A7:":&/85906*L,
MX(P#SUR.^>/8*\&\6:!H_P`+=)E&G7=Q<ZYJD;6\4LQ7-M`?]8R@#AB,+GKR
M<8P<Y_PD\*W'B/7O[3O7E;3-/<,0S';--U5/<#AC_P`!'1JTJT833JQTC^9$
M*LXM4Y:L^B:*^=O%7@3QI?>+=7N[/2[I[::[D>)UN$`92QP0"U<=K6C:_P"'
M)XH=7AN+2252Z*TP;<`<9^4FIAA(SM::N.6(<=XGUU17RAI'A/Q9KUB+W2[*
MZN;8L4\Q9U`R.HP6!J'6_#_B3PXD+ZQ;7-HLY(C+3!MQ&,_=8^HJOJ4;\O.K
MB^LNU^70^M:*\I^!$CR>&M4,CLY^V]6)/_+-:]6KDJP]G-Q['1"7/%2"BO./
MBN[H-)VLRY$^<'']RO14^XOT%7.CR4H5+_%?\#*GB.>M.E;X;?BKCJ**YOQE
MH%]X@T^W@L9H8GCEWL97901@CL#ZUG3BI249.R[FE6<H0<HJ[['2454TJVDL
MM(LK29E:6"!(W922"54`D9^E6ZEJSLBXMM)L****0PKYH^*G@W_A%_$C7%K'
MMTS4"9(0HP(W_CC]@,Y'L<=C7TO7@7QH\8IJFIIX=LW5K:QDWW#C!W3X(V@_
M[()!]R1_#79@G+VMH[=3FQ2CR:G$//K?C[Q/9PRR&YU"=8[:,MG"JHY8^@^\
M[>Y8^U?3_AS0;3PSH-KI-F/W<"X9R.9'/+,?<G)_2OEK1-6U'PAXCM-1BC>.
MX@VNT+C;YD;J#M/LRL"#[@]J^K=(U6TUO2;74[&3S+:YC#H>X]0?0@Y!'8@U
MKCKI12^$SPEG=O<NUX-\>O\`D8-(_P"O5O\`T.O>:\&^/7_(P:1_UZM_Z'6.
M"_C(VQ/\-G:?!3_DGR_]?<O]*P/C]_QYZ#_UUF_DM;_P3_Y)\O\`U]R_TK!^
M/O\`QYZ#_P!=9OY+5P_WOYLSG_N_R+?P%_Y%G5?^O[_VFM>L5Y/\!?\`D6-5
M_P"O[_VFM>L5ABOXTC:A_#1YO\5QG^R!_P!=O_9*6.S\4^,4_M!=0.F:>Y(M
MX5D8$J.,D+C/3J3]!C%-^+'32?\`MM_[)7H&GP+;:;:VZ#"Q0H@'L`!7<ZWL
ML)2:2OKOZGE1H>VQM:,F^7W=%I?30\V.J>(_`VJPQ:K<O?6$W/,A?<!UVEN0
MPR..G/XC>\?ZO<VF@6-WIMX\0FF&)(FQN4HQ'X=*/B=&K>&(7(^9+I2#_P`!
M85SOB&1Y/AEH#.>1(%'T"N!^@%:THQK.E6:5[V?F8UI3H*M04G9*Z[K7N=G/
MXA71?!5EJ=T6FF>VB"J3S+(R`]?S)^AKE=.T[Q7XOB.HSZN]C:N3Y:QLR@X/
M9%(X]R<\52\<2N/#7A>($[/L>\CL2$C`_F?SKU2UMX[2S@MHAB.*-8T'L!@5
MA)K#TE.*7-)O7LDSHA%XJLZ<V^6"6B=KMJ^IYM<7OB?P+>PM>W;:CITK8R[E
M@?;+<JV.0,X/O@X](L[N&_LH;NW??#,@=#['^M87CV%)?!M\7`RFQU)['>/Z
M$C\:K_#F5I/"$2L>(Y9%7Z9S_,FHK6K8=5K6DG9VZFM#FH8IX>[<6KJ_378B
M^)'C%?"'AMG@<?VE=YBM%P#@_P`3D>B@_F5'>O#OAQX4?Q?XL1+E6DL+8BXO
M&;)WC/"$^K']`Q[5]`:[X&\.>);Y;S5]/:YG1!&K&XE4!02<`*P'4GM5S0?#
M.C^&+:6WT>R6UCE?S)!O9RQQCJQ)[=.G7U-94Z\:=)QC\3.N=*4ZB<MD>=?&
MOPB+S38_$MG'^_LU$=T%'WH<\-_P$G\B?[M<[\&?&?\`9FJ'PY?2XM+U]ULS
M'B.;^[]&_P#0@./F->\SP17-O);SQK)#*I1T89#*1@@CTQ7'K\)O!*,K)HI5
ME.0PNYP0?4'?1#$1]DZ=3Y!*E+VG/`[2O!OCU_R,&D?]>K?^AU[R!@8K!U_P
M7X?\3W$-QK&G_:984*1MYTB8!.<?*PK/#U%3J*3+K0<X<J.8^"?_`"3Y?^ON
M7^E8/Q]_X\M"_P"NLW\EKU+1-!TWPYI_V#2K;[/:AR^S>S_,>IRQ)JOK_A31
M?%"0)K-E]J6W+&(>:Z;2<9^Z1GH.M5&M%5_:="94VZ7)U/`O`?Q+;P1IEU9#
M2!>^?/YV\W7E;?E`QC8V>E=7_P`-`/\`]"NO_@Q_^U5VW_"I?`__`$!/_)J;
M_P"+H_X5+X'_`.@)_P"34W_Q=;RK86;YI1=_Z\S.-.O%637]?(\VU;Q^WCLP
M@Z6+'['NZ7'F[]^/]E<8V^_6O5/#GC'3+K2H8[Z\AL[R%!'-'<.(\L.,C..O
MIVIEK\,_"%EO^SZ1LWXW?Z3*<X^K^]7=5\%Z)J]RUS/;,D[<M)"Y4M]1T)]\
M9JYXC#5*<:3325]?Z9R1PV*IUYUHM/FMIKT1R/CG78O$5Q9Z'H[?:F\[<SI]
MUGP0`#W`!))Z=.>#5GQ_8KIO@S2+)2"()4CW#^(B-LG\3S77:1X9TG0V+V-H
M%E88,KDLY'ID]/PQ5C5=&L-;MT@U"#SHT?>J[V7!P1GY2/4U,<73A."@GRQU
M\V.6!JU(5)3:YYJWDD<9XET674_`&CW5NA>:RM8W*CJ4*+NQ],`_0&M+PKXT
MTR\T>"&_O8;:\A0))Y[A`^.`P8\'/IUSGM@UUEO!%:VT5O"NV*)`B+DG"@8`
MY]JP-0\#:!J,[3O9F&1CEC`Y0'\.GZ5"Q%*I#V=6]KMIKI<N6%K4ZBJT6KM)
M-/9VZG-^.O%-MJ-HNB:2_P!KDGD7S&A^8'!R%7'4DXZ>GO78>%]);1?#MI92
M8\Y5+2X_OL<D?AG'X4W2?"NC:++YUG:`3]/-D8NP^A/3\,5LU%:O!TU1I+W5
MKKNV:8?#U%5=>LUS-65MD@HHHKD.X****`"BBB@`HHHH`****`"BBB@`HHHH
+`****`"BBB@#_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
